# Iterum Therapeutics plc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Iterum Therapeutics plc). ## Overview Iterum Therapeutics plc is a biopharmaceutical company focused on developing and commercializing ORLYNVAH™ (sulopenem etzadroxil and probenecid), an oral antibiotic for uncomplicated urinary tract infections in adult women with limited or no alternative oral treatment options. After receiving FDA approval in October 2024, the company launched ORLYNVAH in the U.S. in August 2025 and is now building a commercial organization around sales, distribution, and supply chain execution. ## Products & services • ORLYNVAH™ oral antibiotic for uncomplicated UTI • U.S. commercial launch and sales execution • Third-party commercialization services via EVERSANA • Contract manufacturing and supply via ACS Dobfar • Sulopenem development program for additional indications - **Commercial pharmaceutical product** (85%) — ORLYNVAH™ is the company's approved oral antibiotic product sold in the U.S. for uUTI. - **Commercialization services** (5%) — Sales, marketing, logistics, channel management, and medical affairs support outsourced to EVERSANA. - **Manufacturing and supply chain** (5%) — Contract manufacturing and supply of ORLYNVAH materials through ACS Dobfar and related partners. - **Development-stage pipeline** (5%) — Sulopenem-related research and development for potential future indications and products. - ORLYNVAH™ oral antibiotic for uncomplicated UTI - U.S. commercial launch and sales execution - Third-party commercialization services via EVERSANA - Contract manufacturing and supply via ACS Dobfar - Sulopenem development program for additional indications ## Customers The primary customers are U.S. prescribers and patients in the uncomplicated UTI market, with sales driven through high-volume antibiotic prescribers and the pharmacy/channel system. The company also depends on third-party service providers for distribution, customer service, reimbursement support, and pharmacovigilance, which are essential to getting the product to end users and maintaining compliance. - **Adult women with uncomplicated UTI** (primary) — Patients using ORLYNVAH when limited or no alternative oral antibacterial options are available. - **Prescribers of uUTI antibiotics** (primary) — Physicians and other clinicians targeted for adoption because they drive prescribing volume. - **Payers and government programs** (secondary) — Commercial and public payers that affect formulary access, pricing, rebates, and net revenue. - **Pharmacy and distribution channel** (secondary) — Wholesalers, pharmacies, and fulfillment partners that handle inventory and dispensing. - **Healthcare service providers** (secondary) — EVERSANA and other vendors that manage commercialization, logistics, and compliance functions. - Adult women with uncomplicated UTI who need an oral antibiotic option - High-volume prescribers of uUTI antibiotics targeted by the sales force - Pharmacies and channel partners that dispense ORLYNVAH - Payers and government programs that influence access and reimbursement - Third-party logistics and commercialization partners that enable fulfillment ## Geography Iterum's business is currently centered in the United States, where ORLYNVAH was launched in August 2025 and where the company books sales. The company also relies on international partners for manufacturing and supply, including ACS Dobfar in Europe, while its corporate structure includes non-U.S. subsidiaries used for commercialization and supply arrangements. - United States is the core commercial market for ORLYNVAH - U.S. launch began in August 2025 after FDA approval in 2024 - Sales are booked in the U.S. through Iterum Therapeutics US Limited - Manufacturing and supply involve ACS Dobfar in Europe - Commercial and corporate subsidiaries support cross-border operations ## Strategy The company's near-term strategy is to establish ORLYNVAH in the U.S. market through a focused launch, outsourced commercialization, and a limited geographic sales approach. Longer term, Iterum is trying to expand the sulopenem franchise by pursuing additional indications and potentially adding new product candidates or in-licensed assets. - **Successful U.S. commercialization of ORLYNVAH** (short-term) — The company now needs product uptake to convert its first approved asset into sustainable revenue. - **Build commercial infrastructure and access capabilities** (short-term) — Reimbursement, distribution, and patient access will determine whether the launch can scale beyond early adoption. - **Extend the sulopenem platform** (medium-term) — Additional indications could broaden the addressable market and reduce reliance on a single product. - **Secure supply and manufacturing continuity** (short-term) — A new commercial product requires reliable manufacturing, inventory, and quality control to avoid launch disruption. - Build initial U.S. demand for ORLYNVAH through targeted prescriber outreach - Use EVERSANA to scale sales, logistics, and channel operations efficiently - Expand patient access, reimbursement, and distribution capabilities - Pursue additional sulopenem indications through preclinical and clinical work - Consider in-licensing or acquiring other product candidates or technologies ## Risks Iterum remains a high-risk commercial-stage biotech with a limited operating history, a single marketed product, and substantial dependence on third parties. The company also faces going-concern risk, launch execution risk, reimbursement and pricing pressure, and regulatory/compliance exposure tied to pharmacovigilance, government pricing, and data handling. - **Going concern and financing risk** [critical] — The company has incurred significant losses and has limited product revenue, so it may need additional capital to fund commercialization and development. - **Commercial launch execution risk** [high] — ORLYNVAH is newly launched and sales depend on prescriber uptake, access, and field execution in a competitive antibiotic market. - **Third-party dependence** [high] — EVERSANA, ACS Dobfar, and other vendors handle key commercialization and supply functions outside direct control. - **Government pricing and rebate compliance** [high] — Errors in mandated pricing calculations or reporting could affect rebate liabilities and create False Claims Act exposure. - **Cybersecurity and privacy** [medium] — The company handles patient, commercial, and safety data, and breaches could disrupt operations or trigger legal claims. - **License and IP dependence** [high] — The Pfizer license is central to sulopenem rights and includes diligence, milestone, and royalty obligations. - Going-concern risk reflects ongoing losses and limited revenue history - ORLYNVAH launch may underperform if prescriber adoption is slow - Dependence on EVERSANA and other vendors creates execution and compliance risk - Pricing, rebate, and government reporting errors could trigger sanctions - Single-product concentration increases exposure to product-specific setbacks - Cybersecurity or privacy incidents could disrupt operations and clinical data ## Accounting The most important accounting issues are early-stage product revenue recognition, net revenue deductions, and the estimation of rebates, discounts, and returns now that ORLYNVAH has launched. The company also reports derivative revaluation gains and losses each quarter, and its loss-making profile means valuation allowances, uncertain tax positions, and going-concern disclosures remain important for analysis. - **Net product revenue estimates** — Can materially change gross-to-net deductions and quarterly revenue - **Derivative liability remeasurement** — Adds volatility below operating income and affects balance sheet liabilities - **Valuation allowance on deferred tax assets** — Can materially affect tax expense and equity - **Going-concern assessment** — Affects disclosure risk and investor assessment of financing needs - **Accruals for government pricing and rebates** — Can affect net sales, liabilities, and compliance exposure - Net product revenue depends on estimates for rebates, discounts, and returns - Quarterly derivative revaluation can create non-operating volatility - Launch timing affects when sales, receivables, and COGS begin to appear - Valuation allowances matter because deferred tax assets may not be realized - Going-concern disclosures reflect funding needs and liquidity assumptions --- *Last updated: 2026-04-28T20:18:24.537861+00:00*